Termination of Kuwait study of Avigan in hospitalized patients with moderate to severe COVID-19 Jan. 28, 2021
BLAZE-1 study of bamlanivimab plus etesevimab meets primary endpoint in high-risk COVID-19 Jan. 27, 2021
Vir releases initial phase I data for its HBV-neutralizing monoclonal antibody, VIR-3434 Jan. 27, 2021
TLR2/6 activation using INNA-051 shows promise as prophylactic strategy against COVID-19 Jan. 27, 2021
RSS